Search research articles
Contact Us
Filters
Showing results (1-10 of 39) with videos related to
Page
of 4
Sort By:
Leukemia & Lymphoma
|
January 5, 2026
Management of relapsed/refractory DLBCL in the era of novel agents and new approaches
Inna Y Gong, John Kuruvilla
The Canadian Journal of Cardiology
|
June 25, 2013
Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban
Inna Y Gong, Richard B Kim
Drug Metabolism and Pharmacokinetics
|
October 11, 2012
Impact of genetic variation in OATP transporters to drug disposition and response
Inna Y Gong, Richard B Kim
Basic & Clinical Pharmacology & Toxicology
|
September 11, 2012
Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry
Inna Y Gong, Sara E Mansell, Richard B Kim
Plos One
|
September 15, 2018
Prediction of early breast cancer patient survival using ensembles of hypoxia signatures
Inna Y Gong, Natalie S Fox, Vincent Huang, et al.
Hemasphere
|
August 23, 2024
Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphoma
Inna Y Gong, Daisy Tran, Samuel Saibil, et al.
British Journal of Cancer
|
July 8, 2023
Fracture risk among patients with cancer compared to individuals without cancer: a population-based study
Inna Y Gong, Kelvin K W Chan, Lorraine L Lipscombe, et al.
Diabetologia
|
January 7, 2021
Association between diabetes and haematological malignancies: a population-based study
Inna Y Gong, Matthew C Cheung, Stephanie Read, et al.
Leukemia & Lymphoma
|
August 7, 2023
Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials
Inna Y Gong, Mahmood Aminilari, Ivan Landego, et al.
Breast Cancer Research and Treatment
|
April 3, 2020
Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes
Inna Y Gong, Andrew T Yan, Craig C Earle, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 39) with videos related to
Sort By:
Page
of 4
Leukemia & Lymphoma
|
January 5, 2026
Management of relapsed/refractory DLBCL in the era of novel agents and new approaches
Inna Y Gong, John Kuruvilla
The Canadian Journal of Cardiology
|
June 25, 2013
Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban
Inna Y Gong, Richard B Kim
Drug Metabolism and Pharmacokinetics
|
October 11, 2012
Impact of genetic variation in OATP transporters to drug disposition and response
Inna Y Gong, Richard B Kim
Basic & Clinical Pharmacology & Toxicology
|
September 11, 2012
Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry
Inna Y Gong, Sara E Mansell, Richard B Kim
Plos One
|
September 15, 2018
Prediction of early breast cancer patient survival using ensembles of hypoxia signatures
Inna Y Gong, Natalie S Fox, Vincent Huang, et al.
Hemasphere
|
August 23, 2024
Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphoma
Inna Y Gong, Daisy Tran, Samuel Saibil, et al.
British Journal of Cancer
|
July 8, 2023
Fracture risk among patients with cancer compared to individuals without cancer: a population-based study
Inna Y Gong, Kelvin K W Chan, Lorraine L Lipscombe, et al.
Diabetologia
|
January 7, 2021
Association between diabetes and haematological malignancies: a population-based study
Inna Y Gong, Matthew C Cheung, Stephanie Read, et al.
Leukemia & Lymphoma
|
August 7, 2023
Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials
Inna Y Gong, Mahmood Aminilari, Ivan Landego, et al.
Breast Cancer Research and Treatment
|
April 3, 2020
Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes
Inna Y Gong, Andrew T Yan, Craig C Earle, et al.
Page
of 4